All About Positive Health

Just another Blog Engage Bloggers Club weblog

  • RSS ClinicianOnNet

    • Links for 2012-01-31 [Digg] February 1, 2012
      Bedsores can be Responsible for Considerable Morbidity and Mortality Bedsores can kill almost as many as the hospital superbug MRSA (Methicillin Resistant Staphylococcus Aureus) and cost a lot to the exchequer anywhere in the world. Even when they don’t kill, they inflict terrible pain, discomfort; and rob the sufferer of their time and money. Read more; htt […]
    • Bedsores can be Responsible for Considerable Morbidity and Mortality January 31, 2012
      Bedsores can kill almost as many as the hospital superbug MRSA (Methicillin Resistant Staphylococcus Aureus) and cost a lot to the exchequer anywhere in the world. Even when they don’t kill, they... [[ This is a content summary only. Visit my website for full links, other content, and more! ]] […]
    • Links for 2012-01-30 [Digg] January 31, 2012
      Melatonin and Risk of Developing Diabetes Mellitus In addition to inducing sleep, it also acts on different organs of body and influence their functions too. So it regulates the “biological clock” responsible for sleep/wake pattern. It has been seen that people engaged in night shift duty are prone to develop type II diabetes (DM Type II) mellitus, obesity a […]
  • Get it Delivered to YOU.

    Enter your email address:

    Delivered by FeedBurner

  • Recent Comments

  • Meta


  • 0
    Unique
    Visitors
    Powered By Google Analytics
  • Pages

  • Recently Active Member Avatars

    Member avatar
    Member avatar
    Member avatar
    Member avatar
    Member avatar

Belimumab in Break Through Treatment of SLE

Posted by Dr.Prahallad Panda on June 19, 2010

Systemic lupus erythematosus, an autoimmune disease having far reaching consequences; including financial, somatic and emotional problems. The treatments now available, can keep it suppressed for a long period, but the quality of life does not remain same after the diagnosis.
Prednisolone, a steroid and immuno-suppressants are the mainstays of treatment options available now. This drugs though promising and having some shortfalls, still path breaking in the treatment of SLE. Newer hope arise in the treatment of this ugly disease.
clipped from www.medpagetoday.com
EULAR: Modest Long-Term Benefits for Lupus Drug
ROME — Final results from the closely watched BLISS-76 trial of belimumab (Benlysta) for systemic lupus erythematosus suggested the drug was better than placebo but not by much, it was reported here.
In the first scientific presentation of 76-week data from the phase III study, Ronald van Vollenhoven, MD, of the Karolinska Institute in Stockholm, said about 39% of patients on the investigational drug achieved a response according to the primary outcome measure, compared with 32.4% of those treated with placebo.

Another significant advantage for belimumab was in the percentage of patients able to reduce steroid doses to 7.5 mg/day (prednisone equivalent) or less: 25.8% and 27.7% for the low and high doses, compared with 17.5% of the placebo group (P<0.05).

Nearly all patients in the study experienced some type of adverse event. Severe events were recorded in about 20% of patients, spread equally among the treatment arms.

  blog it

Leave a Reply



XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>